Study Of JK08 In Patients With Unresectable Locally Advanced Or Metastatic Cancer

Study Overview

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced or metastatic cancer.

This Phase 1/2, open label, dose escalation and cohort expansion study is designed to evaluate and characterize the safety, tolerability, PK, pharmacodynamics, immunogenicity, and preliminary antitumor activity of JK08 administered subcutaneously (SC) on a once weekly (QW) schedule in patients with unresectable locally, advanced or metastatic cancer. The study consists of a Dose Escalation phase to determine the MTD/OBD of JK08, followed by a Cohort Expansion phase to further define the safety and initial efficacy of JK08 monotherapy or in combinations.

Cancer
Tumor, Solid
Advanced Solid Tumor
Metastatic Cancer
Melanoma
Colorectal Cancer
Non-small Cell Lung Cancer
Small-cell Lung Cancer
Urothelial Carcinoma
Squamous Cell Carcinoma of Head and Neck
Luminal Breast Cancer
Triple Negative Breast Cancer
Clear Cell Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Gastric Adenocarcinoma
GastroEsophageal Cancer
Squamous Cell Carcinoma Skin
Pancreatic Adenocarcinoma
Hepatocellular Carcinoma
Colorectal Adenocarcinoma
Epithelial Ovarian Cancer
Thyroid Cancer

DRUG: JK08
DRUG: Pembrolizumab
DRUG: Lenvatinib Pill

JK08.1.01
2022-000339-21 (EUDRACT_NUMBER Identifier) (EUDRACT_NUMBER: )

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2022-11-03	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2024-10-11
First Submitted that Met QC Criteria 2022-11-11	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2024-10-15
First Posted (ACTUAL) 2022-11-17	Results First Posted N/A	Last Verified 2024-10

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Non Randomized

Interventional Model:
Sequential

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Dose Escalation Escalating repeated doses of JK08 administered as a subcutaneous injection. A cycle of treatment is defined as 21 days, in which three doses of JK08 will be planned for administration.	DRUG: JK08 Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.
EXPERIMENTAL: Dose Expansion Pembrolizumab Combination Cohort - Non-Small Cell Lung Cancer JK08 administered at the maximum-tolerated dose/recommended Phase 2 dose as a subcutaneous injection in patients with a mix of solid tumors. Pembrolizumab will be given IV per standard institutional practice	DRUG: JK08 Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα. DRUG: Pembrolizumab Immune checkpoint inhibitor
EXPERIMENTAL: Dose Expansion Pembrolizumab Combination Cohort - Colorectal Cancer JK08 administered at the maximum-tolerated dose/recommended Phase 2 dose as a subcutaneous injection in patients with a mix of solid tumors. Pembrolizumab will be given IV per standard institutional practice	DRUG: JK08 Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα. DRUG: Pembrolizumab Immune checkpoint inhibitor
EXPERIMENTAL: Dose Expansion Lenvatinib Combination Cohort - Hepatocellular Cancer JK08 administered at the maximum-tolerated dose/recommended Phase 2 dose as a subcutaneous injection in patients with a mix of solid tumors. Lenvatinib will be given orally per standard institutional practice	DRUG: JK08 Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα. DRUG: Lenvatinib Pill Multi-kinase inhibitor

Primary Outcome Measures	Measure Description	Time Frame
Dose-limiting Toxicity (DLT)	The incidence of DLTs during the DLT assessment period.	First 21 days of treatment.
Dose-Finding	Determination of the maximum-tolerated dose/recommended Phase 2 dose.	Screening to 90 days from last dose.
Safety and Tolerability	Incidence, nature, and severity of treatment-emergent adverse events [TEAEs]. Defined as any AE that occurs during the treatment period (i.e., after any treatment) and up to 28 days after the last dose of study treatment.	First treatment through 28 days after last dose of treatment or End of Treatment [EOT] visit, whichever is later.
Safety and Tolerability	Incidence, nature, and severity of Serious Adverse Events [SAEs].	Screening date through 30 days after last dose of treatment or End of Treatment [EOT] visit, whichever is later.
Safety and Tolerability	Incidence, nature, and severity of adverse events [AEs].	Screening date through 30 days after last dose of treatment or End of Treatment [EOT] visit, whichever is later.

Secondary Outcome Measures	Measure Description	Time Frame
Pharmacokinetics of JK08	Maximum Plasma Concentration (Cmax)	Day 1 of dosing through 21 days post last dose.
Pharmacokinetics of JK08	Area Under the Curve (AUC)	Day 1 of dosing through 21 days post last dose.
Objective Response Rate (ORR)	ORR according to RECIST v1.1.	Day 1 of dosing through every 90 after the last dose.
Disease Control Rate (DCR)	The percentage of patients with a complete response, partial response, or stable disease for at least 2 consecutive tumor assessments.	ay 1 of dosing through every 90 after the last dose.
Progression Free Survival (PFS)	Time from the date of initiation of study therapy to the date measurement criteria are first met for progressive disease or death from any cause, whichever occurs first.	Day 1 of dosing through every 90 after the last dose.
Overall Survival (OS)	Time from the date of initiation of study therapy to the date of death from any cause.	Day 1 of dosing through every 90 after the last dose.

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Non-small cell lung cancer (NSCLC).
Small cell lung cancer (SCLC).
Melanoma.
Clear cell or papillary renal cell carcinoma (RCC).
Urothelial cancer (UC).
Head and neck squamous cell cancer (HNSCC).
Luminal B (ER+, PR-, any HER2 status) or triple-negative breast cancer.
Gastric or gastro esophageal adenocarcinoma (GC/GEJ).
Esophageal squamous cell cancer.
Skin squamous cell carcinoma (SCC).
Pancreatic adenocarcinoma.
Hepatocellular carcinoma (Childs-Pugh A or B7 only).
Colorectal adenocarcinoma (CRC).
Epithelial ovarian cancer.
Cervical cancer.
Endometrial adenocarcinoma.
Thyroid cancer (follicular or papillary). 4. Expansion Combination Cohorts

Albumin ≥ 2.8 g/dL.
Platelet count ≥ 75,000.
Hemoglobin ≥ 8.0 g/dL.
Absolute neutrophil count ≥ 1,500/µL.
ALT/AST ≤ 3.0 times ULN.

ALT/AST ≤ 5 × ULN for patients with liver metastases.
Total bilirubin ≤ 1.5 ULN or ≤ 3 x ULN for patients with Gilbert's disease.

Direct bilirubin ≤ ULN for patients with total bilirubin > 1.5 ULN.
Creatinine ≤ 1.8 mg/dL.

Or calculated/measured creatinine clearance > 30 mL/minute. 9. Identification of an archival tumor sample (i.e., tissue block (formalin-fixed paraffin-embedded [FFPE]) or a series of approximately 10-15 slides). 10. Consent to pre- and on- treatment fresh tumor biopsy for all patients enrolled as back fill in Dose Escalation or for at least 6 additional patients per expansion cohort in Cohort Expansion in Simon Stage 2. Note: Biopsies are not required for the Basket Cohort. 11. Women of childbearing potential (WOCBP) not surgically sterilized and between menarche and 1 year post menopause must:

Have a negative serum or urine pregnancy test performed within 72 hours prior to the initiation of study drug administration.
Be willing to use 2 forms of effective contraception throughout the study, starting with the screening and through 90 days after the last dose of JK08.
Abstinence is considered a highly effective method if this is the established and preferred contraception method for the patient and is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Female and male condoms should not be used together. 12. Male patients with partners of childbearing potential, even if surgically sterilized (i.e., status post-vasectomy) must agree to:

Use effective barrier contraception from the time of consent through 90 days after discontinuation; or
Agree to practice true abstinence, if this is the established and preferred contraception method by the patient and is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. Periodic abstinence [e.g., calendar, symptothermal, post-ovulation methods], withdrawal, spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Female and male condoms should not be used together.
In addition, male patients should also have their partners use contraception for the same period of time. 13. Central nervous system (CNS) metastases must have been treated, be asymptomatic for ≥14 days, and meet the following at the time of enrollment:

No concurrent treatment for CNS disease (e.g., surgery, radiation, corticosteroids ≥ 10 mg prednisone/day or equivalent).
No concurrent or past history of leptomeningeal disease or cord compression. 14. Must be willing and able to comply with clinic visits and procedures outlined in the study protocol. 15. Concurrent use of hormones for breast cancer or for non cancer related conditions (e.g., insulin for diabetes, hormone replacement therapy) is acceptable. Bisphosphonates or RANK-L inhibitor or analogues are permitted for supportive care of patients with bone metastases.

Myocardial infarction or unstable angina.
Clinically significant cardiac arrhythmias.
Uncontrolled hypertension: systolic blood pressure (SBP) > 180 mmHg, diastolic blood pressure (DBP) > 100 mmHg.
Pulmonary embolism, symptomatic cerebrovascular events or any other serious cardiac condition (e.g., pericardial effusion or restrictive cardiomyopathy).
QTcF prolongation > 480 msec.
Congestive heart failure (New York Heart Association class III-IV).
Myocarditis/clinically significant pericarditis. 5. Clinically significant gastrointestinal disorders including:

Gastrointestinal perforation or unhealed ulcerations < 6 months prior to study drug administration. Patients must have documented evidence (e.g., upper endoscopy, colonoscopy) of completely healed area of prior perforation.
Clinically significant gastrointestinal bleeding < 3 months prior to study drug administration.
Pancreatitis < 6 months prior to study drug administration.
History of Crohn's disease or ulcerative colitis. 6. Clinically significant pulmonary compromise requiring supplemental oxygen use. 7. History of Grade 3 or greater drug-related immune-mediated AE during treatment with CPIs such as anti-PD-(L)1 or anti-CTLA-4 antibodies. 8. Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed. At least 2 doses of COVID-19 vaccination must have been completed prior to enrollment (see Section 8.2 for further details). 9. Known hypersensitivity to JK08 or any excipient (histidine/histidine-HCl, sucrose, glycine, PS-80). 10. Second primary invasive malignancy not in remission for ≥ 1 year. Exceptions include non melanoma skin cancer, cervical carcinoma in situ, resected melanoma in situ, or any malignancy considered to be indolent and never required therapy. 11. Any serious underlying medical or psychiatric condition that would preclude understanding and rendering of informed consent or impair the ability of the patient to receive or tolerate the planned treatment. 12. Recent or ongoing serious infection including the following:

Any uncontrolled Grade 3 or higher (per CTCAE v5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of JK08. Routine antimicrobial prophylaxis is allowed.
Uncontrolled infection with human immunodeficiency virus (HIV). Patients on stable highly active antiretroviral therapy (HAART) therapy with undetectable viral load and normal CD4 counts for at least 6 months prior to study entry are eligible. Serological testing for HIV at screening is not required.
Known to be positive for hepatitis B (HBV) surface antigen, or any other positive test for hepatitis B indicating acute or chronic infection. Patients who are or have received anti-HBV therapy and have undetectable HBV DNA for at least 6 months prior to study entry are eligible. Serological testing for hepatitis B at screening is not required.
Known active hepatitis C (HCV) as determined by positive serology and confirmed by polymerase chain reaction (PCR). Patients on or having received antiviral therapy are eligible provided they are virus-free by PCR for at least 6 months prior to study entry. Serological testing for hepatitis C at screening is not required.
Known active or latent tuberculosis (testing at screening not required). 13. Use of systemic corticosteroids within 15 days or other immunosuppressive drugs within 30 days prior to start of the study, with the exception of corticosteroids as replacement therapy up to an equivalent of prednisone 10 mg/day which is allowed. Inhaled, topical, or intraarticular steroids are allowed. 14. Prior systemic anti-cancer treatment as follows:

For cytotoxic chemotherapy, small molecule inhibitors, radiation, or similar investigational treatments, ≤ 2 weeks or 5 half lives, whichever is shorter.
For monoclonal antibodies or similar experimental therapies: ≤ 3 weeks or 5 half-lives, whichever is shorter.
Antibody drug conjugates and radioimmunoconjugates or other similar experimental therapies ≤ 6 weeks or 5 half-lives, whichever is shorter. 15. Ascites or pleural effusions requiring large volume para- or pleurocentesis within 4 weeks of treatment initiation. 16. Pregnant or nursing. 17. Therapeutic anticoagulation for a thromboembolic event that occurred within 3 months of dosing; prophylactic anticoagulation is permitted.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record